183 related articles for article (PubMed ID: 33801465)
1. Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis.
Mataki Y; Kurahara H; Idichi T; Tanoue K; Hozaka Y; Kawasaki Y; Iino S; Maemura K; Shinchi H; Ohtsuka T
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801465
[TBL] [Abstract][Full Text] [Related]
2. Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma.
Yanagimoto H; Satoi S; Yamamoto T; Yamaki S; Hirooka S; Kotsuka M; Ryota H; Ishida M; Matsui Y; Sekimoto M
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32486418
[TBL] [Abstract][Full Text] [Related]
3. 18F-fluorodeoxyglucose positron emission tomography to indicate conversion surgery in patients with initially unresectable locally advanced pancreatic cancer.
Okano K; Suto H; Oshima M; Ando Y; Nagao M; Kamada H; Kobara H; Masaki T; Okuyama H; Okita Y; Tsuji A; Suzuki Y
Jpn J Clin Oncol; 2018 May; 48(5):434-441. PubMed ID: 29590448
[TBL] [Abstract][Full Text] [Related]
4. Survival impact on triple-modal strategy comprising hyperthermia, external radiation, and chemotherapy for unresectable locally advanced (UR-LA) pancreatic ductal adenocarcinoma.
Shimomura O; Oda T; Hashimoto S; Doi M; Hiroshima Y; Numajiri H; Takahashi K; Furuya K; Miyazaki Y; Owada Y; Ogawa K; Ohara Y; Hisakura K; Akashi Y; Enomoto T; Sakurai H
Surg Oncol; 2021 Jun; 37():101542. PubMed ID: 33740629
[TBL] [Abstract][Full Text] [Related]
5. Prognosis of Pancreatic Cancer Based on Resectability: A Single Center Experience.
Einama T; Takihata Y; Aosasa S; Konno F; Kobayashi K; Yonamine N; Fujinuma I; Tsunenari T; Nakazawa A; Shinto E; Ueno H; Kishi Y
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831444
[TBL] [Abstract][Full Text] [Related]
6. Conversion surgery with gemcitabine plus nab-paclitaxel for locally advanced unresectable pancreatic cancer: A case report.
Okura R; Takano S; Yokota T; Yoshitomi H; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Nojima H; Mishima T; Miyazaki M; Ohtsuka M
Mol Clin Oncol; 2018 Oct; 9(4):389-393. PubMed ID: 30214727
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression.
Kobayashi M; Mizuno S; Murata Y; Kishiwada M; Usui M; Sakurai H; Tabata M; Ii N; Yamakado K; Inoue H; Shiraishi T; Yamada T; Isaji S
Pancreas; 2014 Apr; 43(3):350-60. PubMed ID: 24622063
[TBL] [Abstract][Full Text] [Related]
8. Evaluating staging laparoscopy indications for pancreatic cancer based on resectability classification and treatment strategies for patients with positive peritoneal washing cytology.
Igarashi T; Fukasawa M; Watanabe T; Kimura N; Itoh A; Tanaka H; Shibuya K; Yoshioka I; Hirabayashi K; Fujii T
Ann Gastroenterol Surg; 2024 Jan; 8(1):124-132. PubMed ID: 38250680
[TBL] [Abstract][Full Text] [Related]
9. Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma.
Satoi S; Yamamoto T; Yamaki S; Sakaguchi T; Sekimoto M
Ann Gastroenterol Surg; 2020 Jan; 4(1):6-13. PubMed ID: 32021953
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in conversion surgery following nab-paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreatic cancer: Results of a dual-center study.
Igarashi T; Yamada S; Hoshino Y; Murotani K; Baba H; Takami H; Yoshioka I; Shibuya K; Kodera Y; Fujii T
Ann Gastroenterol Surg; 2023 Jan; 7(1):157-166. PubMed ID: 36643365
[TBL] [Abstract][Full Text] [Related]
11. Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis.
Lindemann J; du Toit L; Kotze U; Bernon M; Krige J; Jonas E
HPB (Oxford); 2021 Feb; 23(2):173-186. PubMed ID: 33268268
[TBL] [Abstract][Full Text] [Related]
12. Reappraisal of the validity of surgery for patients with pancreatic cancer aged 80 years or older stratified by resectability status.
Kondo N; Uemura K; Nakagawa N; Okada K; Seo S; Takahashi S; Murakami Y
J Hepatobiliary Pancreat Sci; 2020 Feb; 27(2):64-74. PubMed ID: 31602815
[TBL] [Abstract][Full Text] [Related]
13. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy: a systematic review of the published literature.
Zhou Y; Liao S; You J; Wu H
Updates Surg; 2022 Feb; 74(1):43-53. PubMed ID: 34021484
[TBL] [Abstract][Full Text] [Related]
14. Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus on the 2017 Definition of Borderline Resectable Cancer.
Hayasaki A; Isaji S; Kishiwada M; Fujii T; Iizawa Y; Kato H; Tanemura A; Murata Y; Azumi Y; Kuriyama N; Mizuno S; Usui M; Sakurai H
Cancers (Basel); 2018 Mar; 10(3):. PubMed ID: 29510561
[No Abstract] [Full Text] [Related]
15. Clinical Significance of Histological Effect and Intratumor Stromal Expression of Tenascin-C in Resected Specimens After Chemoradiotherapy for Initially Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma.
Hayasaki A; Murata Y; Usui M; Hibi T; Ito T; Iizawa Y; Kato H; Tanemura A; Azumi Y; Kuriyama N; Kishiwada M; Mizuno S; Sakurai H; Yoshida T; Isaji S
Pancreas; 2018 Apr; 47(4):390-399. PubMed ID: 29517632
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of a locally advanced unresectable pancreatic cancer patient with interstitial pneumonitis by conversion surgery following gemcitabine plus nab-paclitaxel chemotherapy: A case report.
Yokota T; Takano S; Yoshitomi H; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Nojima H; Mishima T; Nakadai E; Ohtsuka M
Mol Clin Oncol; 2019 Apr; 10(4):419-424. PubMed ID: 30931110
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of postoperative complication after pancreatoduodenectomy for pancreatic adenocarcinoma stratified by the resectability status.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Okada K; Takahashi S; Sueda T
J Surg Oncol; 2018 Dec; 118(7):1105-1114. PubMed ID: 29878355
[TBL] [Abstract][Full Text] [Related]
18. Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment.
Asano T; Hirano S; Nakamura T; Okamura K; Tsuchikawa T; Noji T; Nakanishi Y; Tanaka K; Shichinohe T
J Hepatobiliary Pancreat Sci; 2018 Jul; 25(7):342-350. PubMed ID: 29797499
[TBL] [Abstract][Full Text] [Related]
19. Conversion surgery for initially unresectable locally advanced pancreatic ductal adenocarcinoma after chemotherapy followed by carbon-ion radiotherapy: a case report.
Watanabe Y; Tatsuguchi T; Date K; Shinkawa T; Kuga H; Tamiya S; Nishihara K; Nakano T
J Med Case Rep; 2024 Jan; 18(1):13. PubMed ID: 38200536
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?
Konstantinidis IT; Warshaw AL; Allen JN; Blaszkowsky LS; Castillo CF; Deshpande V; Hong TS; Kwak EL; Lauwers GY; Ryan DP; Wargo JA; Lillemoe KD; Ferrone CR
Ann Surg; 2013 Apr; 257(4):731-6. PubMed ID: 22968073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]